These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11527658)

  • 1. Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.
    Stulc T; Melenovský V; Grauová B; Kozich V; Ceska R
    Nutrition; 2001 Sep; 17(9):721-3. PubMed ID: 11527658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate.
    Dierkes J; Westphal S; Kunstmann S; Banditt P; Lössner A; Luley C
    Atherosclerosis; 2001 Sep; 158(1):161-4. PubMed ID: 11500187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
    Melenovsky V; Stulc T; Kozich V; Grauova B; Krijt J; Wichterle D; Haas T; Malik J; Hradec J; Ceska R
    Am Heart J; 2003 Jul; 146(1):110. PubMed ID: 12851616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
    Milionis HJ; Papakostas J; Kakafika A; Chasiotis G; Seferiadis K; Elisaf MS
    J Clin Pharmacol; 2003 Aug; 43(8):825-30. PubMed ID: 12953339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate raises plasma homocysteine levels in the fasted and fed states.
    Bissonnette R; Treacy E; Rozen R; Boucher B; Cohn JS; Genest J
    Atherosclerosis; 2001 Apr; 155(2):455-62. PubMed ID: 11254917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
    Sebestjen M; Keber I; Zegura B; Simcic S; Bozic M; Fressart MM; Stegnar M
    Thromb Haemost; 2004 Nov; 92(5):1129-35. PubMed ID: 15543343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration.
    Mayer O; Simon J; Holubec L; Pikner R; Subrt I
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):367-71. PubMed ID: 12845504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate, homocysteine and renal function.
    Foucher C; Brugère L; Ansquer JC
    Curr Vasc Pharmacol; 2010 Sep; 8(5):589-603. PubMed ID: 20507276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management.
    Dierkes J; Westphal S; Luley C
    Drug Saf; 2003; 26(2):81-91. PubMed ID: 12534325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
    Krysiak R; Okrzesik J; Szkrobka W; Okopień B
    Pharmacol Rep; 2016 Feb; 68(1):185-9. PubMed ID: 26721371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrates and homocysteine.
    Young IS; Woodside JV
    Nutrition; 2001; 17(11-12):973-4. PubMed ID: 11744353
    [No Abstract]   [Full Text] [Related]  

  • 12. Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration.
    Dierkes J; Westphal S; Martens-Lobenhoffer J; Luley C; Bode-Böger SM
    Atherosclerosis; 2004 Apr; 173(2):239-44. PubMed ID: 15064097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
    Dierkes J; Westphal S; Luley C
    Expert Opin Drug Saf; 2004 Mar; 3(2):101-11. PubMed ID: 15006716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis.
    van Ede AE; Laan RF; Blom HJ; Boers GH; Haagsma CJ; Thomas CM; De Boo TM; van de Putte LB
    Rheumatology (Oxford); 2002 Jun; 41(6):658-65. PubMed ID: 12048292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
    Dobordzhginidze LM
    Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838
    [No Abstract]   [Full Text] [Related]  

  • 16. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
    Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Seo YH; Choi IS; Shin EK
    J Am Coll Cardiol; 2005 May; 45(10):1649-53. PubMed ID: 15893182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
    Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Dose folic acid supplementation decreases plasma homocysteine concentrations: a randomised trial.
    Brouwer IA; van Dusseldorp M; Thomas CMG ; Duran M; Hautvast JGAJ ; Eskes TKAB ; Steegers-Theunissen RP
    Indian Heart J; 2000; 52(7 Suppl):S53-58. PubMed ID: 11339442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial.
    Brouwer IA; van Dusseldorp M; Thomas CM; Duran M; Hautvast JG; Eskes TK; Steegers-Theunissen RP
    Am J Clin Nutr; 1999 Jan; 69(1):99-104. PubMed ID: 9925130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recommended dietary allowance of folic acid is insufficient for optimal homocysteine levels].
    Brouwer DA; Welten HT; van Doormaal JJ; Reijngoud DJ; Muskiet FA
    Ned Tijdschr Geneeskd; 1998 Apr; 142(14):782-6. PubMed ID: 9646611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.